No products in your basket.
Purchase your test with
Price range: £955.00 through £1,115.00
The OncoNext Liquid Monitor ctDNA monitoring test is designed only for people who have already been diagnosed with cancer. It checks cell-free DNA in blood for selected tumour-related gene changes that may add information to oncologist-led tumour profiling or monitoring. Four continuing panel options are available.
For the right person, Liquid Monitor provides a private route to additional molecular testing that an oncology team can consider alongside tissue results, scans, symptoms and treatment history. It does not make treatment decisions or prove whether cancer has returned or gone away.
A 10 ml blood sample is required. You can arrange collection with your own qualified healthcare professional or use My DNA Lab’s mobile phlebotomy service within mainland UK. Once your sample is ready, contact us and we will arrange its return to the laboratory.
A tumour may release small pieces of DNA into the blood. This is called circulating tumour DNA, or ctDNA. Liquid Monitor analyses selected genes for tumour-related changes within this cell-free DNA.
Depending on your cancer and chosen panel, the result may add information about the tumour’s molecular profile, track a known gene change over time or identify a possible change linked to treatment resistance. The value of that information depends on the clinical question set by your oncology team.
You can review every gene in the 15-gene, 50-gene, breast and lung panel documents under ‘Test provider and further information’ further down this page.
Because the amount of ctDNA can change for several reasons, and some cancers release very little into the blood, Liquid Monitor cannot decide by itself whether treatment is working, whether cancer remains or whether it has returned.
Liquid Monitor is only suitable if you have already been diagnosed with cancer and are under the care of an oncology team. This ensures that the panel is linked to a defined clinical question and that the result can be interpreted properly.
Your oncologist should choose the panel and define that question before the sample is collected. They will need to consider the report with your cancer type, tissue and pathology results, treatment history, scans and other clinical information.
Liquid Monitor is not a general cancer screening test. If you have not been diagnosed with cancer, this product is not the appropriate route for investigating symptoms or general cancer risk.
My DNA Lab’s mobile phlebotomy service is available within mainland UK for an additional £60. Alternatively, you can arrange collection with your own qualified healthcare professional.
Your report may identify selected tumour-related gene changes that provide additional molecular information for your oncologist. Where an earlier tissue or blood result exists, the oncology team may also be able to compare the findings over time.
A result showing no detected change cannot prove that no cancer remains. The ctDNA level may be too low for detection, or the tumour may carry a change outside your selected panel.
Equally, a detected change does not show on its own whether treatment has worked or failed. Your oncology team may need to compare the finding with scans, symptoms, pathology and other results before deciding what it means.
Do not start, stop or change cancer treatment from this report alone. Liquid Monitor does not replace imaging, tissue biopsy, pathology, clinical review or established follow-up.
Free genetic counselling is available both before and after this test. To use either service, contact My DNA Lab and we will put you in touch with a representative from the testing provider. We always recommend that you discuss your results with your healthcare professional; for Liquid Monitor, the oncology team responsible for your care must interpret the report, and genetic counselling does not replace that review.
Before the sample is collected, your oncology team should define what will be compared. This may be a known tumour gene change, an earlier tissue or blood result, a point in treatment or a question about possible resistance. Using the same panel may also matter when results are compared over time.
Share previous pathology and molecular reports with your oncology team. This can help them choose a matching panel and compare the same question where possible.
ctDNA levels do not always reflect the amount of cancer in a simple way. The report must therefore be read alongside scans, pathology, symptoms and treatment history rather than treated as a standalone measure.
